Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
0.00 | -151.00K | -367.00K | -460.00K | -632.00K | EBIT |
-27.55M | -23.41M | -32.56M | -38.63M | -43.76M | EBITDA |
-27.55M | -26.88M | -40.94M | -42.78M | -5.36M | Net Income Common Stockholders |
-62.29M | -27.03M | -50.05M | -38.20M | -4.82M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
51.96M | 27.15M | 42.30M | 69.45M | 44.26M | Total Assets |
68.91M | 45.55M | 68.24M | 109.45M | 85.53M | Total Debt |
1.12M | 1.37M | 2.60M | 3.65M | 2.31M | Net Debt |
-7.62M | -11.25M | -10.56M | -59.81M | -14.14M | Total Liabilities |
36.34M | 6.87M | 12.13M | 12.29M | 13.38M | Stockholders Equity |
32.57M | 38.68M | 56.12M | 97.16M | 72.15M |
Cash Flow | Free Cash Flow | |||
-25.42M | -23.97M | -27.29M | -36.72M | -34.85M | Operating Cash Flow |
-25.42M | -23.93M | -27.02M | -36.72M | -34.78M | Investing Cash Flow |
-27.48M | 15.54M | -23.28M | 21.56M | 44.77M | Financing Cash Flow |
49.03M | 7.86M | 0.00 | 62.16M | 1.31M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
51 Neutral | $207.92M | ― | -85.03% | ― | -15.39% | 19.42% | |
48 Neutral | $6.86B | 1.11 | -50.22% | 2.47% | 16.71% | 1.53% | |
48 Neutral | $215.03M | ― | -23.06% | ― | 177.89% | -10.95% | |
44 Neutral | $219.77M | ― | -41.48% | ― | 182.62% | -3.67% | |
42 Neutral | $215.99M | ― | -174.85% | ― | ― | -71.53% | |
40 Underperform | $206.25M | ― | -154.01% | ― | 187.79% | 32.40% | |
32 Underperform | $204.63M | ― | -19.08% | ― | ― | 26.63% |
Corvus Pharmaceuticals announced new interim data from its Phase 1 clinical trial of soquelitinib for treating atopic dermatitis, showing a favorable safety and efficacy profile. The data revealed significant improvements in clinically meaningful endpoints compared to placebo, with no safety issues observed, positioning soquelitinib as a potential new treatment for immune diseases.